Clinical Trials
Hair-raising trial results, and Servier’s M&A wishlist
Why are investors excited about hair loss drugs? Will AI make clinical trials run more smoothly? And more in “The Readout LOUD,” STAT’s weekly biotech podcast.
Every story of April 2026, newest first. How AI is changing drug discovery, clinical trials, manufacturing and regulation.
Clinical Trials
Why are investors excited about hair loss drugs? Will AI make clinical trials run more smoothly? And more in “The Readout LOUD,” STAT’s weekly biotech podcast.
Regulation
BioticsAI CEO Robhy Bustami joined Isabelle Johannessen on Build Mode to discuss how the company has navigated a highly regulated space and kept the team motivated while cutting through all the red tape.
Regulation
Surviving the long road to FDA approval isn’t just about building great technology, it’s about keeping your team motivated, finding the right investors, and learning how to operate when timelines are uncertain. This…
Regulation
Surviving the long road to FDA approval isn’t just about building great technology, it’s about keeping your team motivated, finding the right investors, and learning how to operate when timelines are uncertain. This…
Regulation
In this edition of STAT Health Tech: FDA’s plan to use AI to speed up trials, Hinge’s new migraine device, and boosting cancer screening with texts.
Regulation
The FDA is launching a pilot program to monitor clinical trials in real time using AI and cloud computing, a move the agency says could dramatically shorten the time it takes to approve new drugs.
Safety
Acquisition integrates AI-enabled PV solutions with clinical and safety services
Deals
Eli Lilly’s deal with Profluent aims to go beyond CRISPR by using AI-designed enzymes to insert entire genes. It could reshape genetic medicine.
Regulation
The New York Times published a profile of the company Medvi earlier this month, celebrating it as an example of what AI could help a single person do: build a telehealth company its founder projects will be worth $1.8…
Regulation
Platform to support workforce development for quality, production and regulatory roles
Drug Discovery
10x Science has raised a $4.8 million seed round to help pharmaceutical researchers understand complex molecules.
Drug Discovery
OpenAI introduces GPT-Rosalind, a frontier reasoning model built to accelerate drug discovery, genomics analysis, protein reasoning, and scientific research workflows.
Regulation
When Grammy-nominated singer-songwriter Aloe Blacc got COVID despite being vaccinated and boosted, he tried to fund research for a better solution. What he quickly found out? You can’t just write a check in biotech…
Industry
These products have yet to offer treatment solutions designed to get users from their current health state to a desired future health state. This creates a massive, untapped opening for tools that move people from…
Clinical Trials
To address the clinical burden and enhance R&D, companies are turning to virtual solutions. This involves synthetic data, digital twin models, and AI to speed analysis.
Regulation
The FDA told more than 2,200 companies and researchers that they are required to report clinical trial results, or they may face fines
Drug Discovery
Amazon Web Services today launched Amazon Bio Discovery, an application that routes AI-designed antibody candidates directly to DNA Synthesis firm Twist Bioscience and the techbio Ginkgo Bioworks for synthesis and…
Drug Discovery
On March 29, Insilico Medicine announced a drug discovery deal with Eli Lilly that gives the Big Pharma firm an exclusive worldwide license to a portfolio of preclinical oral therapeutics. The collaboration also sets up…
Regulation
While many AI conversations revolve around regulated industry transformation, the question is where to actually start in a way that does not break trust, budgets or regulatory limits.
Regulation
In this edition of Health Tech: FDA rejects a proposal to deregulate certain types of AI devices, pharma invests $50 million in DTx, and more.
Industry
As AI reshapes pharma, HR leadership is being drawn into a deeper question that goes beyond technology to the future of people and work, finds Lakshmipriya Nair
Deals
Anthropic is paying 400 million dollars for an eight-month-old biotech startup with fewer than ten employees. The investor walks away with a 38,513 percent return.
Regulation
In 2024, OpenAI CEO Sam Altman predicted that a single entrepreneur using AI would generate a business worth more than one billion dollars. The L.A. entrepreneur Matthew Gallagher apparently is boasting that his…
Deals
Anthropic has purchased the stealth biotech AI startup Coefficient Bio in a $400 million stock deal, according to The Information and Eric Newcomer.
Regulation
In this edition of STAT Health Tech: Another study of AI scribes, and an analysis of AI-powered devices that got FDA’s ‘breakthrough’ label.
Regulation
An analysis of AI-powered devices that received FDA’s “breakthrough” label shows a preference for big-picture, multi-problem solutions.
Industry
In this edition of STAT’s AI Prognosis: How to be a ‘productive’ biotech AI company, with Insilico Medicine CEO Alex Zhavoronkov, and more.
No stories match these filters.
Subscribe on YouTube, or get an email the day each new lesson goes live.
Ask ai2hired
Answers from this site only, with the pages they come from.
Hi! I can help with the free course: lessons, seasons, career paths, workbooks, credentials, the free tools and your account.
AI answers can be wrong: check the linked page. Not stored. Need a person? info@ai2hired.org